On 26 April 2023, the European Commission adopted a proposal for a new Directive and Regulation, which revises and replaces the existing general pharmaceutical legislation. The proposals seek to ensure that EU citizens have equal access to safe and effective medicines, tackle the slow rollout of innovative therapies, and manage shortages and the rising costs of medicines.
The proposals were developed against a backdrop of a global health pandemic and periods of significant geopolitical upheaval. The EU also faces several other ongoing challenges, such as an ageing population, growing concerns around anti-microbial resistance, dependence on non-EU countries for medicines and the increasing pressures on health systems. There is also a necessity to drive forward European R&D and harness the role of digital technologies.
This latest session of the Bayer Life Talks assessed the prevailing perspectives on the pharmaceutical strategy, looking at how it can balance access to medicines while boosting competitiveness. The interactive roundtable discussion focused on what the proposals will mean for innovation, access to critical medicines and ensuring a resilient European pharmaceutical industry, as well as the opportunities presented by innovative medicines and self-care solutions in that regard.
15:00 – 15:05
15:05 – 16:30
Roundtable Discussion & Q&A
Event Close & Networking Coffee
Note: All session timings below are in Central European Summer Time (CEST)
Head of Unit,
Governmental and Public Affairs Manager
Vice President, Governmental Affairs
Bayer Consumer Health
CEO, Thirst Foundation
Chairman, Forum Europe
Secretary-General, World Meteorological Organization
Vice President, Copa
Executive Vice President, Public Affairs, Science, Sustainability & HSE, Bayer AG
SDG Water Investments Specialist, Global Water Partnership Southern Africa
For more information on any aspect of the Bayer Life Talks series, please contact us using the details below: